Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BAVA.CO
- Price
- 239.70
- Stock movement up
- +0.55 (0.29%)
- Company name
- Bavarian Nordic
- Exchange
- (CO ,
- Currency
- DKK )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 14.86B
- Ent værdi
- 15.49B
- Pris/omsætning
- 2.30
- Pris/bog
- 1.23
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- 10.44
- Fremtidig P/E
- 19.44
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- -8.22%
- 3 års afkast
- -
- 5 års afkast
- -
- 10 års afkast
- -
Senest opdateret: 2025-11-11
UDBYTTE
BAVA.CO betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | 10.44 |
| Pris til OCF | 8.41 |
| Pris til FCF | - |
| Pris til EBITDA | 7.12 |
| EV i forhold til EBITDA | 7.42 |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 2.30 |
| Pris til egenkapital | 1.23 |
| EV i forhold til salg | 2.40 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 78.24M |
| EPS (TTM) | - |
| FCF pr. aktie (TTM) | - |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | - |
| Bruttofortjeneste (TTM) | - |
| Driftsindkomst (TTM) | - |
| Nettoindkomst (TTM) | - |
| EPS (TTM) | - |
| EPS (1 år frem) | 9.77 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | - |
| Driftsmargin (TTM) | - |
| Fortjenstmargin (TTM) | - |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 1.22B |
| Nettotilgodehavender | 904.22M |
| Omsætningsaktiver i alt | 5.52B |
| Goodwill | 0.00 |
| Immaterielle aktiver | 6.13B |
| Ejendomme, anlæg og udstyr | 2.20B |
| Sum aktiver | 13.91B |
| Kreditor | 1.10B |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 1.65B |
| Sum gæld | 1.86B |
| Aktionærernes egenkapital | 12.05B |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | - |
| Investeringsudgifter (TTM) | - |
| Fri pengestrøm (TTM) | - |
| Udbetalt udbytte (TTM) | - |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | - |
| Afkast af aktiver | - |
| Afkast af investeret kapital | - |
| Kontant afkast af investeret kapital | - |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 193.35 |
| Daglig høj | 193.35 |
| Daglig lav | 189.75 |
| Daglig volumen | 621K |
| Højeste gennem alle tider | 401.70 |
| 1 års analytiker estimat | 250.00 |
| Beta | 1.10 |
| EPS (TTM) | - |
| Udbytte pr. aktie | 0.00 |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 14 Nov 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| BAVA.CO | S&P500 | |
| Nuværende prisfald fra top notering | -40.33% | -1.10% |
| Højeste prisfald | -65.11% | -19.00% |
| Højeste efterår dato | 7 Apr 2025 | 8 Apr 2025 |
| Gennemsnitlig fald fra toppen | -51.20% | -2.76% |
| Gennemsnitlig tid til nyt højdepunkt | - | 5 days |
| Maks. tid til nyt højdepunkt | 272 days | 89 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
14.86B
Markedsværdi kategori
Large-cap
Beskrivelse
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Personale
1667
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Denmark
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
COPENHAGEN, Denmark, November 7, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley th...
7. november 2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COP...
6. november 2025
COPENHAGEN, Denmark, November 1, 2025 – Bavarian Nordic A/S hereby issues the following clarification regarding the Health Emergency Preparedness and Response Authority (HERA) framework agreement, ann...
1. november 2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COP...
31. oktober 2025
New and larger framework contract with the European Commission’s Health Emergency Preparedness and Response Authority (HERA) replaces previous agreement and provides for up to 8 million doses of small...
31. oktober 2025
COPENHAGEN, Denmark, October 28, 2025 – Bavarian Nordic announced today a donation of mpox vaccines to Africa CDC to support the response to the ongoing mpox outbreak in Africa. The donation of 110,00...
28. oktober 2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COP...
21. oktober 2025
Bavarian Nordic (CPSE:BAVA) shares have caught some extra interest lately, especially after their strong run over the past 3 months. Investors are weighing recent performance as the landscape for phar...
16. oktober 2025
ATP’s rejection of a sweetened bid from private-equity firms for the vaccine maker casts doubt over whether the deal will go through.
16. oktober 2025
A consortium led by Nordic Capital and Permira has raised its bid, though certain shareholder stances remain firm.
16. oktober 2025
Næste side